DOCETAXEL ANHYDROUS

SynDRA canonical compound SYN0000498 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	TUBB
Mechanism of action	Tubulin inhibitor
Indication	breast cancer \| gastric adenocarcinoma \| head and neck squamous cell carcinoma (HNSCC) \| non-small cell lung cancer (NSCLC) \| prostate cancer
Disease area	oncology

All known targets

docetaxel
docetaxel hydrate
docetaxol
docetere
taxotel
taxotere
RP-56976
Bind 014
Cabazitaxel metabolite (rp56976)
Docetaxel kabi
Docetaxel mylan
Docetaxel teva pharma
Docetaxel, anhydrous
Rp56976
CKD-810
NSC-628503
Docefrez
Docetaxel winthrop
Docetaxel
EmDOC
TXL
Taxotere
ANX-514
Docetaxel (INN)
Docetaxel, Trihydrate
SDP-014
Taxotere (TN)
Taxotere(R)
XRP-6976L
Docetaxel 114977-28-5
N-debenzoyl-N-Boc-10-deacetyl taxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
docetaxil
Docetaxol
RP 56976